The Molecular Structure of Zaleplon (CAS NO.151319-34-5):


Empirical Formula: C₁₇H₁₅N₅O
Molecular Weight: 305.3339
IUPAC Name: N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide   
Appearance: Off-White Powder
Nominal Mass: 305 Da
Average Mass: 305.3339 Da
Monoisotopic Mass: 305.12766 Da 
Index of Refraction: 1.655
Molar Refractivity: 89.66 cm³
Molar Volume: 244 cm³
Surface Tension: 50.9 dyne/cm
Density: 1.25 g/cm³ 
InChI
InChI=1/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
Smiles
n12c(c3cc(N(C(C)=O)CC)ccc3)ccnc1c(C#N)cn2 
Synonyms: N-[3-(3-cyano-pyrazolo[1,5-a]pyrimidin-7-yl)-phenyl]-n-ethyl-acetamide ; Sonata ; N-[3-(3-cyanopyrazolo[1,5-a]py;zaleplon and intermediates ; N-[3-(3-cyanopyrazolo-[1,5-a]pyrimidin-7-yl)phenyl)-n-ethylacetamide 
Product Categories: Active Pharmaceutical Ingredients;Zaleplon;Intermediates & Fine Chemicals;Pharmaceuticals

 Zaleplon (CAS NO.151319-34-5) is mainly used for insomnia where difficulty in falling asleep is the primary complaint.Unlike many other hypnotic drugs, it does not interfere with sleep architecture and can be administered for up to 5 weeks without the risk of dependence or rebound insomnia upon discontinuation. Zaleplon (CAS NO.151319-34-5) has advantages over benzodiazepines in that it does not disrupt sleep architecture unlike benzodiazepines which whilst inducing sleep actually worsen the quality of it.

Hazard Codes: Xi 
Risk Statements: 36/37/38 
R36/37/38: Irritating to eyes, respiratory system and skin
Safety Statements: 26-36 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
S36: Wear suitable protective clothing

There are also some side effects which are similar to the side effects of benzodiazepines.:
 Zaleplon (CAS NO.151319-34-5) is habit-forming, meaning addiction or drug dependence may occur. Stopping this medication suddenly after prolonged or frequent use may cause withdrawal effects such as mood changes, restlessness,anxietyor rebound insomnia. Zaleplon (CAS NO.151319-34-5) may cause hallucinations,severe confusion,abnormal behavior, day-time drowsiness, dizziness or lightheadedness, unsteadiness and/or falls, double vision or other vision problems, agitation, vomiting, headache, nausea, muscle weakness,diarrhea or abdominal pain, tremor, depression,  vivid or abnormal dreams and memory difficulties or amnesia. However, Zaleplon (CAS NO.151319-34-5) is safer than other nonbenzodiazepine Z drugs with evidence suggesting that tolerance and rebound effects do not occur or if they do are much less frequent than with other drugs in its class.